These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1272 related articles for article (PubMed ID: 22217937)

  • 21. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
    Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
    Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
    Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
    Miller WR; Larionov A
    Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
    Liu R; Guo CX; Zhou HH
    Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.
    Kalyuga M; Gallego-Ortega D; Lee HJ; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Launchbury R; Statham AL; Armstrong N; Alles MC; Young A; Egger A; Au W; Piggin CL; Evans CJ; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JM; Nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ
    PLoS Biol; 2012; 10(12):e1001461. PubMed ID: 23300383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
    McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H
    Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
    Schrijver W; Schuurman K; van Rossum A; Droog M; Jeronimo C; Salta S; Henrique R; Wesseling J; Moelans C; Linn SC; van den Heuvel M; van Diest P; Zwart W
    Mol Oncol; 2018 Nov; 12(11):1884-1894. PubMed ID: 29972720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
    Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
    Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
    D'Amato NC; Gordon MA; Babbs B; Spoelstra NS; Carson Butterfield KT; Torkko KC; Phan VT; Barton VN; Rogers TJ; Sartorius CA; Elias A; Gertz J; Jacobsen BM; Richer JK
    Mol Cancer Res; 2016 Nov; 14(11):1054-1067. PubMed ID: 27565181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
    Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
    Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
    Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
    Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications.
    Badve S; Nakshatri H
    J Clin Pathol; 2009 Jan; 62(1):6-12. PubMed ID: 18794199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
    Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
    Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
    Jing X; Liang H; Hao C; Hongxia L; Cui X
    Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
    Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
    Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.